157 related articles for article (PubMed ID: 11982890)
1. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy.
Tsukahara H; Kimura K; Todoroki Y; Ohshima Y; Hiraoka M; Shigematsu Y; Tsukahara Y; Miura M; Mayumi M
Pediatr Int; 2002 Jun; 44(3):247-53. PubMed ID: 11982890
[TBL] [Abstract][Full Text] [Related]
2. [Effect of carbamazepine and valproate on bone metabolism in children with epilepsy].
Song XQ; Wang ZP; Bao KR; Zhang JM; Wu J; Yan CH; Shen XM
Zhonghua Er Ke Za Zhi; 2005 Oct; 43(10):728-32. PubMed ID: 16255847
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral metabolism changes in epileptic children receiving valproic acid.
Oner N; Kaya M; Karasalihoğlu S; Karaca H; Celtik C; Tütüncüler F
J Paediatr Child Health; 2004 Aug; 40(8):470-3. PubMed ID: 15265190
[TBL] [Abstract][Full Text] [Related]
4. BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy.
Lambrinoudaki I; Kaparos G; Armeni E; Alexandrou A; Damaskos C; Logothetis E; Creatsa M; Antoniou A; Kouskouni E; Triantafyllou N
Eur J Neurol; 2011 Jan; 18(1):93-8. PubMed ID: 20500803
[TBL] [Abstract][Full Text] [Related]
5. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy.
Pack AM; Morrell MJ; Randall A; McMahon DJ; Shane E
Neurology; 2008 Apr; 70(18):1586-93. PubMed ID: 18443309
[TBL] [Abstract][Full Text] [Related]
6. Effect of oxcarbazepine on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy.
Koo DL; Hwang KJ; Han SW; Kim JY; Joo EY; Shin WC; Lee HW; Seo DW; Hong SB
Epilepsy Res; 2014 Mar; 108(3):442-7. PubMed ID: 24507862
[TBL] [Abstract][Full Text] [Related]
7. The effect of valproate on bone mineral density in adult epileptic patients.
Boluk A; Guzelipek M; Savli H; Temel I; Ozişik HI; Kaygusuz A
Pharmacol Res; 2004 Jul; 50(1):93-7. PubMed ID: 15082034
[TBL] [Abstract][Full Text] [Related]
8. The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin.
Phabphal K; Geater A; Limapichart K; Sathirapanya P; Setthawatcharawanich S; Witeerungrot N; Thammakumpee N; Leelawattana R
Epilepsia; 2013 Feb; 54(2):249-55. PubMed ID: 23281616
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.
Välimäki MJ; Tiihonen M; Laitinen K; Tähtelä R; Kärkkäinen M; Lamberg-Allardt C; Mäkelä P; Tunninen R
J Bone Miner Res; 1994 May; 9(5):631-7. PubMed ID: 8053391
[TBL] [Abstract][Full Text] [Related]
10. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy.
Guo CY; Ronen GM; Atkinson SA
Epilepsia; 2001 Sep; 42(9):1141-7. PubMed ID: 11580761
[TBL] [Abstract][Full Text] [Related]
11. Long-term anticonvulsant therapy leads to low bone mineral density--evidence for direct drug effects of phenytoin and carbamazepine on human osteoblast-like cells.
Feldkamp J; Becker A; Witte OW; Scharff D; Scherbaum WA
Exp Clin Endocrinol Diabetes; 2000; 108(1):37-43. PubMed ID: 10768830
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of bone mineral metabolism in children receiving carbamazepine and valproic acid.
Erbayat Altay E; Serdaroğlu A; Tümer L; Gücüyener K; Hasanoğlu A
J Pediatr Endocrinol Metab; 2000; 13(7):933-9. PubMed ID: 10968482
[TBL] [Abstract][Full Text] [Related]
13. Effect of carbamezapine and valproic acid on bone mineral density, IGF-I and IGFBP-3.
Kumandas S; Koklu E; Gümüs H; Koklu S; Kurtoglu S; Karakukcu M; Keskin M
J Pediatr Endocrinol Metab; 2006 Apr; 19(4):529-34. PubMed ID: 16759039
[TBL] [Abstract][Full Text] [Related]
14. The effect of topiramate monotherapy on bone mineral density and markers of bone and mineral metabolism in premenopausal women with epilepsy.
Heo K; Rhee Y; Lee HW; Lee SA; Shin DJ; Kim WJ; Song HK; Song K; Lee BI
Epilepsia; 2011 Oct; 52(10):1884-9. PubMed ID: 21692779
[TBL] [Abstract][Full Text] [Related]
15. Antiepileptic drug-induced osteopenia in ambulatory epileptic children receiving a standard vitamin D3 supplement.
Tekgul H; Dizdarer G; Demir N; Ozturk C; Tutuncuoglu S
J Pediatr Endocrinol Metab; 2005 Jun; 18(6):585-8. PubMed ID: 16042326
[TBL] [Abstract][Full Text] [Related]
16. Effect of carbamazepine and valproate on bone mineral density.
Sheth RD; Wesolowski CA; Jacob JC; Penney S; Hobbs GR; Riggs JE; Bodensteiner JB
J Pediatr; 1995 Aug; 127(2):256-62. PubMed ID: 7636651
[TBL] [Abstract][Full Text] [Related]
17. The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine.
Serin HM; Koç ZP; Temelli B; Esen İ
Epilepsy Behav; 2015 Oct; 51():221-4. PubMed ID: 26298867
[TBL] [Abstract][Full Text] [Related]
18. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy.
Triantafyllou N; Lambrinoudaki I; Armeni E; Evangelopoulos EM; Boufidou F; Antoniou A; Tsivgoulis G
J Neurol Sci; 2010 Mar; 290(1-2):131-4. PubMed ID: 20056251
[TBL] [Abstract][Full Text] [Related]
19. A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy.
Kim SH; Lee JW; Choi KG; Chung HW; Lee HW
Epilepsy Behav; 2007 Mar; 10(2):291-5. PubMed ID: 17224308
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of bone turnover in epileptic children using oxcarbazepine.
Cansu A; Yesilkaya E; Serdaroğlu A; Hirfanoğlu TL; Camurdan O; Gülbahar O; Gücüyener K; Cinaz P
Pediatr Neurol; 2008 Oct; 39(4):266-71. PubMed ID: 18805365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
